Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Nov 08, 2021 1:27pm
618 Views
Post# 34100795

Gasser Group's New Approach to PDC Delivery to Cancer Cells

Gasser Group's New Approach to PDC Delivery to Cancer CellsThe Gasser Group at the Chimie Paris Tech led by Gilles Gasser is very similar to the MccFarland Research Group at the University of Texas Arlington led by Sherri McFarland. They are both investigating the use of metal complexes for medicinal purposes.

In this recent article they explore a new cancer specific photodynamic drug delivery system by coupling a ruthenium based photosensitizer with the aptamer AS1411. Aptamers are molecules which bind to specific targets and AS1411 has been demonstrated to bind to breast and prostate cancer cells leaving normal cell lines unaffected.

AbstractA ruthenium-oligonucleotide bioconjugated photosensitizing aptamer for cancer cell specific photodynamic therapy

Full paperPDF format

<< Previous
Bullboard Posts
Next >>